Biophytis
About Biophytis
Biophytis Is A Biotechnology Company Created In 2006. It Develops First-In-Class Drugs To Treat Degenerative Illnesses Associated With Aging For Which There Is Currently No Treatment. Its Two Most Advanced Programmes Relate To Sarcopenia (Loss Of Muscle Functionality) And Age-Related Macular Degeneration (ARMD).YEAR FOUNDED:
2006
LEADERSHIP:
CEO: Stanislas Veillet PhD
CSO: Rene Lafont
Chief Medical Officer: Susanna Del Signore
130 articles about Biophytis
-
Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity
4/18/2024
Biophytis SA announces the formation of a new Scientific Advisory Board to support the advancement of its phase 2 OBA clinical study in obesity.
-
Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
4/8/2024
Biophytis SA (Nasdaq:BPTS)(Euronext Growth Paris: ALBPS), ("Biophytis" or the "Company") today announces that it is launching a new clinical development program named OBA, with BIO101 (20-hydroxyecdysone) as a potential treatment for obesity in combination with GLP-1 receptor agonists.
-
Results of the Combined General Meeting on April 2, 2024
4/4/2024
Biophytis SA announces the approval of all the resolutions presented by the Company and falling within the remit of the Ordinary and Extraordinary General Meeting.
-
Biophytis Presented its Phase 3 Protocol in the Treatment of Sarcopenia
3/22/2024
Biophytis SA presented its phase 3 protocol aimed at demonstrating the potential of RuvembriTM in the treatment of sarcopenia at the International Conference on Frailty and Sarcopenia Research, held from March 20 to 22, 2024 in Albuquerque, NM, USA.
-
Biophytis Announces Receipt of Nasdaq Notice - November 17, 2023
11/17/2023
Biophytis SA announced that it has received written notification from the Nasdaq Stock Market LLC dated November 15, 2023, indicating that, based upon a closing bid price of less than $1.00 per share for the Company's American Depositary Shares for the prior 30 consecutive business days period, the Company no longer satisfies Nasdaq Listing Rule 5550.
-
Biophytis Receives Notice of Delisting From Nasdaq and Announces It Will Request a Hearing Before the Nasdaq Hearings Panel
10/27/2023
Biophytis SA announces that it has received a notice of delisting from Nasdaq.
-
Biophytis Releases Its Half-Yearly Accounts as of 30 June 2023 and Provides an Update on Its Operations
9/27/2023
Biophytis SA publishes its half-year accounts as of 30 June 2023 and provides an update on the progress of its R&D projects over the 1st half of the year and the last few months.
-
Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)
9/25/2023
Biophytis SA and Skyepharma announce the signature of a partnership agreement for the production of regulatory batches of Sarconeos for severe forms of Covid-19, with a view to the submission of marketing authorization applications.
-
Biophytis Provides an Update on its Early Access Programs for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19
9/19/2023
Biophytis SA announced that it has received a response from the French National Authority for Health to its request for Early Access Authorization in France for patients suffering from severe forms of COVID-19 and provides an update on its strategy in other countries.
-
Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer
9/14/2023
Biophytis SA today announced the strengthening of its management team with the appointment of Edouard Bieth as Chief Business Officer and member of the Executive Committee.
-
Biophytis Announces Next Regulatory Steps in Europe and the United States for its COVA Project
8/16/2023
Biophytis SA announced that it has received feedback from the European Medicines Agency and the Food and Drug Administration enabling it to plan the next regulatory steps for its COVA project dedicated to the development of Sarconeos for severe forms of Covid-19.
-
Biophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe
8/8/2023
Biophytis SA, announced that it has received a positive opinion from Belgian authorities to conduct its SARA-31 program, which will be the first phase 3 study ever launched in sarcopenia.
-
Biophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19
7/20/2023
Biophytis SA announced that it has filed for a pre-submission meeting request with the Food and Drug Administration to discuss filing for Emergency Use Authorization in the United States for Sarconeos in the treatment of severe forms of COVID-19.
-
Biophytis Announces $3.8 Million Registered Direct Offering
7/19/2023
Biophytis SA announced that it has entered into definitive agreements for the purchase and sale of 1,333,334 units, each consisting of one American Depositary Share or one prefunded warrant giving right to one ADS and one warrant to purchase one ADS, at a purchase price of $2.85 per unit comprising an ADS and $2.84 per unit comprising a prefunded warrant.
-
Biophytis and SEQENS Sign a Partnership to Produce Sarconeos (BIO101) Active Compound
7/18/2023
Biophytis SA announced the conclusion of a master agreement for the production of the active compound in Sarconeos, Biophytis' main drug candidate developed for three indications: severe forms of Covid-19, sarcopenia and Duchenne muscular dystrophy.
-
Biophytis Has Filed with The FDA For Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia
7/10/2023
Biophytis SA announced that it has filed for approval on the Food and Drug Administration portal to launch its SARA-31 program in the U.S., the first ever Phase 3 study in sarcopenia.
-
Biophytis Reports Clinical Results for Sarconeos (BIO101) in Sarcopenia Treatment at the 16th SCWD International Congress
6/19/2023
Biophytis SA announces that it is taking part in the 16th SCWD international congress, a flagship event bringing together experts from all over the world to share thoughts, research and innovations on sarcopenia, cachexia and wasting disorders.
-
Biophytis: Results of the Annual General Meeting on June 16, 2023 All Resolutions Presented by the Company Have Been Adopted
6/16/2023
Biophytis SA announces the approval by a very large majority of all resolutions presented by the company and falling within the remit of the Annual General Meeting.
-
Biophytis to Participate at the BIO International Convention in Boston from the 5th to the 8th of June
6/5/2023
Biophytis SA announces it will participate at the Biotechnology Innovation Organization International Convention to be held in Boston from the 5th to the 8th of June 2023, alongside thousands of world leaders in biotechnology and the pharmaceutical industry.
-
Biophytis has Filed with the French National Authority for Health (HAS) an Application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19
5/26/2023
Biophytis SA announced that it has filed, through its pharmaceutical partner Intsel Chimos, an application for Early Access Authorisation in France with the French National Authority for Health for the use of Sarconeos [1] in the treatment of adult patients with a severe form of COVID-19, who are at risk of developing a critical form of the disease and for whom therapeutic alternatives are not appropriate.